Haemonetics Valuation
| HAE Stock | USD 65.39 0.53 0.80% |
At this time, the firm appears to be undervalued. Haemonetics retains a regular Real Value of $75.99 per share. The prevalent price of the firm is $65.39. Our model calculates the value of Haemonetics from evaluating the firm fundamentals such as Return On Asset of 0.0633, return on equity of 0.14, and Current Valuation of 4.22 B as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Haemonetics' valuation include:
Price Book 3.6518 | Enterprise Value | Enterprise Value Ebitda 14.2689 | Price Sales 2.4111 | Forward PE 13.1926 |
Undervalued
Today
Please note that Haemonetics' price fluctuation is very steady at this time. Calculation of the real value of Haemonetics is based on 3 months time horizon. Increasing Haemonetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Haemonetics stock is determined by what a typical buyer is willing to pay for full or partial control of Haemonetics. Since Haemonetics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Haemonetics Stock. However, Haemonetics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 65.39 | Real 75.99 | Target 110.8 | Hype 64.73 | Naive 70.12 |
The real value of Haemonetics Stock, also known as its intrinsic value, is the underlying worth of Haemonetics Company, which is reflected in its stock price. It is based on Haemonetics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Haemonetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Haemonetics helps investors to forecast how Haemonetics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Haemonetics more accurately as focusing exclusively on Haemonetics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Haemonetics' intrinsic value based on its ongoing forecasts of Haemonetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Haemonetics' closest peers. If more than one evaluation category is relevant for Haemonetics we suggest using both methods to arrive at a better estimate.
Haemonetics Cash |
|
Haemonetics Valuation Trend
Comparing Haemonetics' enterprise value against its market capitalization is a good way to estimate the value of Haemonetics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Haemonetics Revenue by Product
Haemonetics Total Value Analysis
Haemonetics is currently forecasted to have company total value of 4.22 B with market capitalization of 3.31 B, debt of 807.79 M, and cash on hands of 284.47 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Haemonetics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.22 B | 3.31 B | 807.79 M | 284.47 M |
Haemonetics Investor Information
About 99.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 18.05. The company has Price/Earnings To Growth (PEG) ratio of 1.1. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012. Based on the key indicators related to Haemonetics' liquidity, profitability, solvency, and operating efficiency, Haemonetics is performing exceptionally good at this time. It has a great probability to report excellent financial results in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 107 M | 209 M |
|
|
Haemonetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Haemonetics has an asset utilization ratio of 59.62 percent. This indicates that the Company is making $0.6 for each dollar of assets. An increasing asset utilization means that Haemonetics is more efficient with each dollar of assets it utilizes for everyday operations.Haemonetics Ownership Allocation
The majority of Haemonetics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Haemonetics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Haemonetics. Please pay attention to any change in the institutional holdings of Haemonetics as this could imply that something significant has changed or is about to change at the company.Haemonetics Profitability Analysis
The company reported the last year's revenue of 1.31 B. Total Income to common stockholders was 117.56 M with profit before taxes, overhead, and interest of 768.33 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Haemonetics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Haemonetics and how it compares across the competition.
About Haemonetics Valuation
The stock valuation mechanism determines Haemonetics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Haemonetics. We calculate exposure to Haemonetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Haemonetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 795.3 M | 835 M | |
| Pretax Profit Margin | 0.07 | 0.12 | |
| Operating Profit Margin | 0.06 | 0.06 | |
| Net Profit Margin | 0.05 | 0.08 | |
| Gross Profit Margin | 0.46 | 0.57 |
Haemonetics Quarterly Retained Earnings |
|
Haemonetics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Haemonetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 51.4 M | |
| Quarterly Earnings Growth Y O Y | 0.213 | |
| Forward Price Earnings | 13.1926 |
Haemonetics Current Valuation Indicators
Valuation refers to the process of determining the present value of Haemonetics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Haemonetics we look at many different elements of the entity such as Haemonetics's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Haemonetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Haemonetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Haemonetics' worth.Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |